The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Offer details
Expected size of offer (M): 2.5m
Expected first date of trading: 14/12/2012
Market: AIM
Location of address at which admission document will be available: Venn Life Sciences Holdings Plc, 14 Kinnerton Place South, London SW1X 8EH Zeus Capital Limited, 3 Ralli Courts, West Riverside, Manchester M3 5FT www.vennlifesciences.com
Date at which admission document will be available: -

Advisors
Sponsor: -
Nominated Advisor (AIM Companies): Zeus Capital Limited
Nominated Broker (AIM Companies): Zeus Capital Limited
Financial PR Advisors: -

Company details
Name Role
David Eric Evans Non Executive Chairman
Anthony (Tony) Francis Richardson Chief Executive Officer
Paul Andrew Peter Foulger Finance Director
Michael (Mike) Ryan Non Executive Director

Facts and Figures
Fiscal year end: 31 December
Incorporated in: UK
Website URL: www.vennlifesciences.com
space
Description of business:
Venn Life Sciences Holdings plc's wholly owned subsidiaries operate two types of business: - a CRO (Contract Research Organisation) business that provides clinical trial management and performance services, to pharmaceutical, medical device and biotechnology companies; and - a clinical resourcing business that supplies clinical staff to organisations that require additional resources...

Person(s) interested:
Name As at the date of this Admission Document (%) Immediately Following Admission (%) Helium Special Situations Fund Ltd 15.38 1.66 Rathbone Brothers Plc 13.85 1.49 Richard Hughes 10.00 1.08 Hawk Investment Holdings Ltd 7.69 0.83 Nick Mustoe 7.69 0.83 Glynn Hirsch 7.69 0.83 Paul Foulger 1 6.92 1.74 Adam Reynolds 2 6.92 1.08 JM Finn & Co 4.62 0.50 Zeus Capital Ltd 3.85 0.41 Hub Capital Partners Ltd 2 3.85 0.41 Daron Lee 3.08 0.33 Laura Deegan 1 3.08 0.33 David Newton 0 12.52 William Fleming Approved Retirement Fund 0 8.50 (1) Laura Deegan is a related party of Paul Foulger as his partner. (2) Adam Reynolds is interested in 12.9% of the issued share capital of Hub Capital Partners.


Venn Life Sciences Holdings plc

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds